Compare GoPro Inc (GPRO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Novavax Inc — how do they compare? GoPro Inc trades at $0.69 (market cap $122.03M), while Novavax Inc trades at $8.27 (market cap $1.39B). The key difference: Novavax Inc is far larger — about 11.4× GoPro Inc's market cap, and Novavax Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| GPRO | NVAX | |
|---|---|---|
Market Cap | $122.03M | $1.39B |
Sector | Technology | Health |
52-Week High | $2.88 | $11.19 |
52-Week Low | $0.64 | $6.22 |
Enterprise Value | $169.98M | $890.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.6978, down 1.86% on the day, reflecting persistent bearish sentiment amid financial distress. The stock shows a negative technical trend with recent earnings misses and declining revenues. The company is undergoing a strategic review for a potential sale or merger, with the CEO providing $20 million in financing to support operations. Valuation ratios like P/E of 4.56 and P/S of 0.18 appear low, but profitability remains deeply negative with a net income margin of -20.7% and ROE of -236.05%.
The outlook is highly speculative, hinging on the success of the strategic review; a sale could unlock value, but ongoing cash burn and competitive pressures pose significant risks. Investors face a binary outcome: potential upside from a strategic transaction versus substantial downside if the company fails to stabilize.
Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.
The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
